High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report
about
Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience.Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS.Aggressive multiple sclerosis: proposed definition and treatment algorithm.The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders.A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple SclerosisDimethyl fumarate selectively reduces memory T cells in multiple sclerosis patientsReport: Stem cell applications in neurological practice, an expert group consensus appraisalFunctional Maturation of Induced Pluripotent Stem Cell Hepatocytes in Extracellular Matrix-A Comparative Analysis of Bioartificial Liver Microenvironments.High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.Autologous hematopoietic cell transplantation in multiple sclerosis.Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow TranLong-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications.Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation.Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.Feasibility and toxicity of hematopoietic stem cell transplant in multiple sclerosis.Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases.Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics.Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.Long-term follow-up more than 10 years after HSCT: a monocentric experience.Cell-based therapeutic strategies for multiple sclerosis.Autologous haematopoietic stem cell transplantation for neurological diseases.Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis.NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.Updated views on autologous hematopoietic stem cell transplantation for treatment of multiple sclerosis.Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-Commentary.Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES.Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant.[Stem cell transplantation for multiple sclerosis. Hamburg experiences and state of international research].Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - YES.Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO.Zelldepletion und Myeloablation bei neuroimmunologischen ErkrankungenEthical rejections of xenotransplantation? The potential and challenges of using human-pig chimeras to create organs for transplantation
P2860
Q28071992-F94B80D4-D94D-4AC0-85D1-AEFA8661397EQ31075436-DFE0EB08-448A-4D94-86DB-A9843C784D20Q33632470-8FE452B4-9878-4A12-82CF-FA89C3096227Q34478828-78711E59-72F4-4F74-B8A3-04A4D2A73767Q34500124-E39FA20A-1716-4236-BD3A-345DCA04A3CBQ35747637-036C283E-B1AA-4409-84BD-E9AFAE59720BQ36484443-DBCC2416-14BF-4AFB-BDA5-DF1AF22D3CA4Q36792169-3955B7BB-2100-4433-896B-0A0C787BC44CQ37167381-E4F2B85A-1C58-4F5F-90B3-CF555500B0C8Q37200883-B2D66AFC-E415-42BC-9A48-9DE04DAA35F8Q37673801-127AEB05-16B0-4F90-B773-B1DB45CA4349Q38636103-24D366E7-0C5A-4859-8014-E045A8D76106Q38666303-BCDEEF65-3CCD-4561-8D78-4082C0452D80Q38818703-A9A947AE-AB07-439A-A96F-CCF452CD4E0DQ38893873-23B56583-36E1-449D-B7A6-3CDC1F7BCD7EQ38939585-0B53FDFF-AE8D-4DA0-AD70-A37F09A3B52CQ39085433-647B9881-3A1A-4CE8-A7AF-F0FDD2D8B836Q39302587-536C2F69-4EFF-4019-9B42-3E213B587D91Q39378263-1A4C4188-39C2-4530-A520-0A723E946A98Q40041536-43C405CD-14C7-49A2-B9AA-25E6152631B0Q40177200-7F199085-2B20-407D-8893-57BAA92462BCQ41010737-ABCDF8AA-587F-4498-8F9D-8E92446E2EDAQ41236543-27C8E82E-B7F2-4A89-9824-435875CBE4BCQ45066717-1C69010E-513F-4299-ACCE-A75180CC3FC4Q46216694-182E1BB2-4802-41BF-8172-BB0839749D67Q46301560-22F9C294-AF57-45C6-A93B-2C0B17942217Q47261875-C274C2A7-EB9A-4221-A053-A9185DC76D34Q47885870-F56AFD87-44B8-4AB5-9AF5-CC6BC9A1BBB1Q48136043-D4518B90-E4AD-4247-8B12-4A754A4BAE5FQ48271331-58AA8F35-672F-450B-8EC6-E9F68300C128Q48721170-6E935D46-8202-4CCE-98FE-0CC5DE309015Q48881267-39283A7D-3337-4F2A-88F4-EAA2A6151583Q50800626-F5F4439A-D68D-4707-A13C-38FCCE53E24CQ50800638-7353B8E3-583B-41FD-AC9F-CC84C44B1405Q52624498-4CCD5D34-1262-4E01-AB0B-1D105E5E7E8AQ52944830-3CE851C2-4A78-4B41-B60B-0F53EFFAFDE5Q53063104-515D617A-14F6-4E6F-BD80-66391523D013Q53063105-6990383C-BD77-4B68-8F9B-AC0D766C1268Q57912843-37C6682D-BD4C-4C14-9437-80ED0E4D4953Q58657258-A096CD39-F16E-49E4-8C85-0BF12F292B45
P2860
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High-dose immunosuppressive th ...... T-MS): a 3-year interim report
@en
High-dose immunosuppressive th ...... g-remitting multiple sclerosis
@nl
type
label
High-dose immunosuppressive th ...... T-MS): a 3-year interim report
@en
High-dose immunosuppressive th ...... g-remitting multiple sclerosis
@nl
prefLabel
High-dose immunosuppressive th ...... T-MS): a 3-year interim report
@en
High-dose immunosuppressive th ...... g-remitting multiple sclerosis
@nl
P2093
P2860
P1433
P1476
High-dose immunosuppressive th ...... T-MS): a 3-year interim report
@en
P2093
Annette Wundes
Deborah Phippard
Douglas L Arnold
George E Georges
George H Kraft
George J Hutton
Harry Openshaw
James D Bowen
Kaitlyn C McConville
Kristina M Harris
P2860
P304
P356
10.1001/JAMANEUROL.2014.3780
P407
P50
P577
2015-02-01T00:00:00Z